{"id":42150,"date":"2023-09-14T14:43:59","date_gmt":"2023-09-14T07:43:59","guid":{"rendered":"https:\/\/hmm88i.com\/drug\/?post_type=product&p=42150"},"modified":"2025-07-24T14:03:48","modified_gmt":"2025-07-24T07:03:48","slug":"thuoc-exforge-5mg-80mg","status":"publish","type":"product","link":"https:\/\/hmm88i.com\/drug\/thuoc-exforge-5mg-80mg\/","title":{"rendered":"Exforge 5mg\/80mg"},"content":{"rendered":"
Trong b\u00e0i vi\u1ebft n\u00e0y, d\u01b0\u1ee3c s\u0129 L\u01b0u V\u0103n Ho\u00e0ng gi\u1edbi thi\u1ec7u \u0111\u1ebfn c\u00e1c b\u1ea1n s\u1ea3n ph\u1ea9m thu\u1ed1c Exforge 5mg\/80mg \u0111\u01b0\u1ee3c s\u1ea3n xu\u1ea5t b\u1edfi Novartis Farmaceutica S.A., c\u00f3 s\u1ed1 \u0111\u0103ng k\u00fd l\u01b0u h\u00e0nh t\u1ea1i Vi\u1ec7t Nam l\u00e0 VN-16344-13<\/strong><\/p>\n Thu\u1ed1c Exforge 5mg\/80mg<\/strong> c\u00f3 ch\u1ee9a th\u00e0nh ph\u1ea7n:<\/p>\n D\u1ea1ng b\u00e0o ch\u1ebf: Vi\u00ean n\u00e9n bao phim<\/p>\n S\u0110K: VN-16344-13 Exforge 5mg\/80mg k\u1ebft h\u1ee3p gi\u1eefa nh\u00f3m thu\u1ed1c ch\u1eb9n k\u00eanh canxi l\u00e0 ho\u1ea1t ch\u1ea5t amlodipin v\u00e0 nh\u00f3m thu\u1ed1c \u0111\u1ed1i kh\u00e1ng v\u1edbi th\u1ee5 th\u1ec3 angiotensin II l\u00e0 valsartan, 2 ch\u1ea5t n\u00e0y c\u00f3 t\u00e1c d\u1ee5ng hi\u1ec7p \u0111\u1ed3ng, b\u1ed5 tr\u1ee3 trong vi\u1ec7c l\u00e0m gi\u1ea3m huy\u1ebft \u00e1p v\u00e0 c\u00f3 hi\u1ec7u qu\u1ea3 t\u1ed1t h\u01a1n so v\u1edbi d\u00f9ng m\u1ed7i th\u00e0nh ph\u1ea7n \u0111\u01a1n \u0111\u1ed9c. Amlodipin ch\u1eb9n k\u00eanh Ca2+ \u1edf m\u00e0ng t\u1ebf b\u00e0o l\u00e0m gi\u00e3n m\u1ea1ch t\u1eeb \u0111\u00f3 l\u00e0m h\u1ea1 huy\u1ebft \u00e1p. Valsartan c\u00f3 t\u00e1c d\u1ee5ng ch\u1ecdn l\u1ecdc tr\u00ean AT1, \u1ee9c ch\u1ebf qu\u00e1 tr\u00ecnh chuy\u1ec3n angiotesin I th\u00e0nh angiotesin II l\u00e0m gi\u00e3n m\u1ea1ch, h\u1ea1 huy\u1ebft \u00e1p.<\/p>\n Valsartan v\u00e0 amlodipin c\u00f3 s\u1ef1 tuy\u1ebfn t\u00ednh trong d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc. Sau khi u\u1ed1ng Exforge 5mg\/80mg, n\u1ed3ng \u0111\u1ed9 valsartan v\u00e0 amlodipine l\u1ea7n l\u01b0\u1ee3t \u0111\u1ea1t \u0111\u1ec9nh sau 3 gi\u1edd v\u00e0 6-8 gi\u1edd. T\u1ed1c \u0111\u1ecd v\u00e0 s\u1ef1 h\u1ea5p thu t\u01b0\u01a1ng t\u1ef1 khi d\u00f9ng ri\u00eang r\u1ebd. Valsartan<\/p>\n Exforge 5mg\/80mg d\u00f9ng trong \u0111i\u1ec1u tri t\u0103ng huy\u1ebft \u00e1p v\u00f4 c\u0103n<\/p>\n Ng\u01b0\u1eddi b\u1ecb t\u0103ng huy\u1ebft \u00e1p \u0111ang \u0111ang d\u00f9ng 1 thu\u1ed1c \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb (\u0111\u01a1n tr\u1ecb li\u1ec7u) kh\u00f4ng hi\u1ec7u qu\u1ea3 th\u00ec c\u00f3 th\u1ec3 \u0111i\u1ec1u tr\u1ecb ph\u1ed1i h\u1ee3p b\u1eb1ng Exforge. \u0110\u01b0\u1ee3c khuy\u1ebfn c\u00e1o l\u00e0 d\u00f9ng 1 vi\u00ean\/ ng\u00e0y v\u00ec Amlodipin v\u00e0 valsartan \u0111\u1ec1u kh\u00f4ng b\u1ecb \u1ea3nh h\u01b0\u1edfng b\u1edfi th\u1ee9c \u0103n, n\u00ean u\u1ed1ng Exforge v\u1edbi \u00edt n\u01b0\u1edbc v\u00e0 th\u1eddi \u0111i\u1ec3m nh\u1ea5t \u0111\u1ecbnh trong ng\u00e0y. Khuy\u1ebfn c\u00e1o d\u00f9ng \u1edf li\u1ec1u th\u00f4ng th\u01b0\u1eddng v\u00ec c\u1ea3 valsartan v\u00e0 amlodipine \u0111\u1ec1u \u0111\u01b0\u1ee3c h\u1ea5p thu t\u1ed1t d\u1ea1ng k\u1ebft h\u1ee3p khi d\u00f9ng n\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi li\u1ec1u th\u1ea5p nh\u1ea5t c\u1ee7a amlodipin v\u00e0 th\u1eadn trong khi t\u0103ng li\u1ec1u.<\/p>\n Khuy\u1ebfn c\u00e1o kh\u00f4ng d\u00f9ng cho b\u1ec7nh nh\u00e2n <18 tu\u1ed5i.<\/p>\n Th\u1eadn tr\u1ecdng khi d\u00f9ng cho ng\u01b0\u1eddi b\u1ecb suy gan ho\u1eb7c c\u00e1c r\u1ed1i lo\u1ea1n t\u1eafc m\u1eadt. Kh\u00f4ng d\u00f9ng cho ng\u01b0\u1eddi suy gan n\u1eb7ng<\/p>\n V\u1edbi ng\u01b0\u1eddi b\u1ecb suy th\u1eadn nh\u1eb9 \u0111\u1ebfn trung b\u00ecnh khi d\u00f9ng Exforge kh\u00f4ng c\u1ea7n hi\u1ec7u ch\u1ec9nh li\u1ec1u nh\u01b0ng c\u1ea7n theo d\u00f5i n\u1ed3ng \u0111\u1ed9 kali v\u00e0 creatinin<\/p>\n Ng\u01b0\u1eddi qu\u00e1 m\u1eabn c\u1ea3m v\u1edbi d\u1eabn xu\u1ea5t dihydropyridin, ho\u1ea1t ch\u1ea5t valsartan v\u00e0 amlodipine ho\u1eb7c b\u1ea5t k\u1ef3 th\u00e0nh ph\u1ea7n n\u00e0o c\u1ee7a thu\u1ed1c. \u0110\u1ecdc k\u1ef9 h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng tr\u01b0\u1edbc khi d\u00f9ng. \u0110\u00e2y l\u00e0 thu\u1ed1c k\u00ea \u0111\u01a1n d\u00f9ng theo ch\u1ec9 \u0111\u1ecbnh c\u1ee7a b\u00e1c s\u0129, h\u1ecfi \u00fd ki\u1ebfn b\u00e1c s\u0129 tr\u01b0\u1edbc khi d\u00f9ng<\/p>\n Nhi\u1ec5m khu\u1ea9n v\u00e0 nhi\u1ec5m k\u00fd sinh tr\u00f9ngB\u1ea1n n\u00ean th\u00f4ng b\u00e1o v\u1edbi b\u00e1c s\u0129 b\u1ea5t k\u1ef3 v\u1ea5n \u0111\u1ec1 s\u1ee9c kh\u1ecfe n\u00e0o b\u1ea1n \u0111ang g\u1eb7p ph\u1ea3i \u0111\u1ec3 \u0111\u01b0\u1ee3c t\u01b0 v\u1ea5n v\u00e0 s\u1eed d\u1ee5ng thu\u1ed1c t\u1ed1t nh\u1ea5t. S\u1ef1 k\u1ebft h\u1ee3p c\u1ee7a amlodipin v\u00e0 valsartan trong Exforge 5mg\/80mg \u0111\u01b0\u1ee3c \u0111\u1ed1i ch\u1ee9ng qua 5 nghi\u00ean c\u1ee9u l\u00e2m s\u00e0ng v\u1edbi 5175 b\u1ec7nh nh\u00e2n v\u00e0 c\u00f3 2613 ng\u01b0\u1eddi s\u1eed d\u1ee5ng k\u1ebft h\u1ee3p amlodipin v\u00e0 valsartan<\/p>\nExforge 5mg\/80mg l\u00e0 thu\u1ed1c g\u00ec?<\/h2>\n
Th\u00e0nh ph\u1ea7n<\/h3>\n
\n
Tr\u00ecnh b\u00e0y<\/h3>\n
\nQuy c\u00e1ch \u0111\u00f3ng g\u00f3i: H\u1ed9p 2 v\u1ec9 x 14 vi\u00ean n\u00e9n bao phim
\nXu\u1ea5t x\u1ee9: Novartis Farmaceutica S.A.<\/p>\nT\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c Exforge 5mg\/80mg<\/h2>\n
C\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng<\/h3>\n
\u0110\u1eb7c \u0111i\u1ec3m d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc<\/h3>\n
\nAmlodipin<\/p>\n\n
\n
Thu\u1ed1c Exforge 5mg\/80mg \u0111\u01b0\u1ee3c ch\u1ec9 \u0111\u1ecbnh trong b\u1ec7nh g\u00ec?<\/h2>\n
Li\u1ec1u d\u00f9ng c\u1ee7a thu\u1ed1c Exforge 5mg\/80mg<\/h2>\n
\nT\u00f9y t\u00ecnh tr\u1ea1ng tr\u00ean l\u00e2m s\u00e0ng c\u00f3 th\u1ec3 chuy\u1ec3n t\u1eeb \u0111\u01a1n tr\u1ecb li\u1ec7u sang ph\u1ed1i h\u1ee3p b\u1eb1ng Exforge v\u1edbi li\u1ec1u c\u1ed1 \u0111\u1ecbnh.B\u1ec7nh nh\u00e2n \u0111ang d\u00f9ng c\u1ea3 hai thu\u1ed1c Amlodipin v\u00e0 valsartan d\u1ea1ng ri\u00eang l\u1ebb c\u00f3 th\u1ec3 chuy\u1ec3n sang Exforge c\u00f3 c\u00f9ng th\u00e0nh ph\u1ea7n v\u1edbi li\u1ec1u t\u01b0\u01a1ng \u1ee9ng \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb.<\/p>\nNg\u01b0\u1eddi cao tu\u1ed5i (> 65 tu\u1ed5i)<\/h3>\n
Tr\u1ebb em v\u00e0 thanh thi\u1ebfu ni\u00ean<\/h3>\n
Ng\u01b0\u1eddi suy gan<\/h3>\n
Suy th\u1eadn<\/h3>\n
Kh\u00f4ng s\u1eed d\u1ee5ng thu\u1ed1c Exforge 5mg\/80mg trong tr\u01b0\u1eddng h\u1ee3p n\u00e0o?<\/h2>\n
\nNg\u01b0\u1eddi b\u1ecb x\u01a1 gan, suy gan n\u1eb7ng ho\u1eb7c \u1ee9 m\u1eadt.
\nNg\u01b0\u1eddi b\u1ecb h\u1ea1 huy\u1ebft \u00e1p n\u1eb7ng
\nS\u1ed1c (c\u1ea3 s\u1ed1c do tim)
\nNg\u01b0\u1eddi b\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng ho\u0103c suy th\u1eadn n\u1eb7ng (GFR<60 ml\/ph\u00fat\/1,73 m2) \u0111ang d\u00f9ng aliskiren..
\nPh\u1ee5 n\u1eef mang thai trong 3 th\u00e1ng v\u00e0o gi\u1eefa v\u00e0 3 th\u00e1ng cu\u1ed1i trong th\u1eddi gian mang thai
\nNg\u01b0\u1eddi g\u1eb7p v\u1ea5n \u0111\u1ec1 v\u1ec1 tim nh\u01b0 suy tim kh\u00f4ng \u1ed5n \u0111\u1ecbnh sau nh\u1ed3i m\u00e1u c\u01a1 tim, t\u1eafc ngh\u1ebdn th\u1ea5t tr\u00e1i nh\u01b0 h\u1eb9p \u0111\u1ed9ng m\u1ea1ch ch\u1ee7 \u1edf t\u00ecnh tr\u1ea1ng n\u1eb7ng,c\u01a1 tim ph\u00ec \u0111\u1ea1i t\u1eafc ngh\u1ebdn.<\/p>\nL\u01b0u \u00fd \u0111\u1eb7c bi\u1ec7t khi s\u1eed d\u1ee5ng thu\u1ed1c Exforge 5mg\/80mg<\/h2>\n
Th\u1eadn tr\u1ecdng<\/h3>\n
\nB\u1ec7nh nh\u00e2n gi\u1ea3m th\u1ec3 t\u00edch m\u00e1u ho\u1eb7c gi\u1ea3m n\u1ed3ng \u0111\u1ed9 natri trong m\u00e1u
\nNg\u01b0\u1eddi t\u0103ng kali m\u00e1u
\nB\u1ec7nh nh\u00e2n h\u1eb9p \u0111\u1ed9ng m\u1ea1ch th\u1eadn, ng\u01b0\u1eddi b\u1ecb suy th\u1eadn
\nB\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c gh\u00e9p th\u1eadn
\nSuy gan
\nPh\u00f9 m\u1ea1ch
\nNg\u01b0\u1eddi c\u00f3 m\u1ed9t trong s\u1ed1 c\u00e1c v\u1ea5n \u0111\u1ec1 v\u1ec1 tim sau: suy tim\/ sau nh\u1ed3i m\u00e1u c\u01a1 tim, nh\u1ed3i m\u00e1u c\u01a1 tim c\u1ea5p t\u00ednh, h\u1eb9p van \u0111\u1ed9ng m\u1ea1ch ch\u1ee7 v\u00e0 h\u1eb9p van 2 l\u00e1, b\u1ec7nh c\u01a1 tim ph\u00ec \u0111\u1ea1i t\u1eafc ngh\u1ebdn
\nPh\u1ee5 n\u1eef c\u00f3 thai
\nC\u01b0\u1eddng aldosteron ti\u00ean ph\u00e1t
\n\u1ee8c ch\u1ebf k\u00e9p h\u1ec7 renin-angiotensin-aldosteron (RAAS)<\/p>\nT\u00e1c d\u1ee5ng ph\u1ee5<\/h3>\n